getting to the heart of the matter
Novel therapeutics and diagnostics targeting the multi-factorial root causes of CVD
the Arterez approach
Cardiovascular disease (CVD), particularly coronary heart disease (CHD) remains the No. 1 disease killer and is rising in the world. By 2030, 23.6 million people are predicted to die from CVD. In the U.S., 42% of all deaths annually are a direct result of CVD; one person dies every 33 seconds from heart disease and it is the leading cause of death for all Americans age 35 and older.
While current symptom-targeted drugs are at best palliative, Arterez has developed a novel 3x compound, synthetic oral therapy and companion bio-marker panel targeting the multi-factorial root causes of CVD.
"Historical development of antibiotics targeting microorganisms led to a cure of infectious disease. An equivalent approach is to target the endothelial glycocalyx to cure CVD by an anti-embolic™ mechanism."
Dr. Joe Tunac
Offerings and IP Summary
IP Matter Description
A rationally synthesized, triple compound, oral therapy with unique mechanisms of action targeting the root causes of CVD proven to prevent and reverse arterial plaques, the hallmark of CVD.
A therapeutic aide and series of diagnostic panels that provide specific information on the associated pathology and risk factors of CVD diseases and stages based on our Glycalyx Detritus Fingerprint™ technology.
Drug Treatment and Biomarker Panel Targeted
to Diseases Due to Multifactorial Ontology of
Biomarkers of Vascular Disease.
Methods and Compositions for Reversing
Disruption of the Glycocalyx, Inflammation and
(Draft - to be published Q2, 2020) Natural Animal Model for CVD and Inflammation.
In The News